Vincristin

Phase 3Small molecule

GGuangzhou Lupeng Pharmaceutical Company LTD.

Vincristin is one of 117 small molecule programs targeting Adult Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

LymphomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Follicular LymphomaActive, not recruiting

Adult Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 1/Phase 2

Active, not recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Vincristin

GGuangzhou Lupeng Pharmaceutical Company LTD.

Phase 3

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Diffuse Large B-Cell Lymphoma

NCT06594640

Q4 2029

Phase 1Recruiting

Lymphoma

NCT06251180

Q2 2030

Recruiting

Adult Acute Lymphoblastic Leukemia

NCT05959720

Q2 2034

Phase 3Recruiting

Follicular Lymphoma

NCT06284122

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma2 trials

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06594640·108 enrolled

Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT00575406·94 enrolled

Follicular Lymphoma1 trial

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06284122·790 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Recruiting·IInstituto do Cancer do Estado de São Paulo··NCT05959720·180 enrolled

Lymphoma1 trial

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Recruiting·GGuangzhou Lupeng Pharmaceutical Company LTD.·Phase 1·NCT06251180·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Vincristin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vincristin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vincristin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Lupeng Pharmaceutical Company LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGuangzhou Lupeng Pharmaceutical Company LTD.

Vincristin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Q2 2030

Q2 2034

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma2 trials

Follicular Lymphoma1 trial

Adult Acute Lymphoblastic Leukemia1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News